Dr. Karnes' primary area of research interest is cardiovascular pharmacogenomics, specifically investigating the utility of genetic polymorphisms to predict toxicities of cardiovascular drugs. He employs a translational approach to investigate pharmacogenomic associations using observational studies, functional genomics techniques, and eventually prospective clinical trials. His ultimate career goal is to facilitate personalized cardiovascular medicine and genotype-guided prescribing to avoid serious cardiovascular drug toxicities.
Dr. Karnes is an author on 34 peer-reviewed manuscripts and 32 abstracts presented at national and international meetings. He is active in multiple professional societies including the American Society for Clinical Pharmacology and Therapeutics, the American Heart Association, and the American College of Clinical Pharmacy. He has received funding for his research from the National Institutes of Health, the American Heart Association, the Flinn Foundation, and the American College of Clinical Pharmacy.
Research Fellowship, Division of Clinical Pharmacology, Vanderbilt University School of Medicine (Tennessee), 2015
PhD, Clinical Pharmaceutical Sciences, University of Florida College of Pharmacy, 2012
PharmD (Cum Laude), University of Florida College of Pharmacy, 2008
BA, Ancient Greek, College of William and Mary (Virginia), 2004
Clinical and Translational Research
Adverse Drug Reactions